Triple threat: new combo therapy targets rare lung cancer

NCT ID NCT03760575

Recruiting now Disease control Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 21, 2026 · Updated 27 times

Summary

This early-phase trial is testing whether adding the immunotherapy drug pembrolizumab and a special image-guided surgery to standard chemotherapy is safe and works for people with malignant pleural mesothelioma, a rare cancer of the lung lining. About 20 adults with measurable tumors will receive the combination treatment. The main goal is to check for side effects, while also tracking how long people live without the cancer growing and overall survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MESOTHELIOMAS PLEURAL are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Abramson Cancer Center of the University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MESOTHELIOMAS PLEURAL